Original-Research: Cantourage Group SE (von NuWays AG): Buy
|
Original-Research: Cantourage Group SE - from NuWays AG
Classification of NuWays AG to Cantourage Group SE
9M prelims: Growth further accelerating, FY guidance specified Topic: Cantourage released preliminary Q3 figures, which were marked by >100% yoy sales growth and further sequential improvements thanks to the partial legalization that took place in April. With this, the company is well on track to reach EBITDA profitability this year. In detail: Q3 sales jumped by 124% yoy to € 13.2m (9M sales +75% yoy to € 30.1m). The significant growth was primarily fuelled by the partial legalization of medical cannabis in Germany, which took effect at the end of April. This change has made obtaining a prescription for medical cannabis as straightforward as getting one for ibuprofen 600. On top, Cantourage is also experiencing a sharp increase in demand at its treatment facility in UK. Further, Cantourage is well on track to turn profitable despite significant growth investments. In Q3, EBITDA is seen to come in at around € 1m (mid-point of guidance). For the FY, management expects to reach EBITDA break-even (eNuW: € 1.8m). FY24 guidance specified towards the upper end. The company’s initial FY24 sales guidance stood at € 37-43m (eNuW: € 43m). With € 30m sales after the first nine months and the past two months alone having contributed some € 10m, management specified the guidance towards the upper end, now targeting at least € 40m sales. Taking into account sequentially increasing sales volumes and the strong operational performance during recent months, we regard our estimate as well in reach. With the current runrate, our sales estimate of € 54m for FY25e (26% yoy growth) already look achievable. Mid-term to be marked by further strong growth. Assuming a somewhat similar development of the German medical cannabis market as in US states, the market offers a € 1.2-1.4bn opportunity. Over the past two years, Cantourage has laid the foundation to achieve €100 million in sales. With a global network of over 60 growers, Cantourage offers a diverse range of cannabis flowers, minimizing cluster risks. Through its recent partnership with Portocanna, the company can now process approximately 14 tons of flowers annually. Additionally, Cantourage's own telemedicine platform, telecan°, connects the company directly with patients, offering easy access to cannabis therapy consultations and prescriptions. We confirm our BUY rating with an unchanged € 10 PT based on DCF. You can download the research here: http://www.more-ir.de/d/31025.pdf For additional information visit our website: www.nuways-ag.com/research Contact for questions: NuWays AG - Equity Research Web: www.nuways-ag.com Email: research@nuways-ag.com LinkedIn: https://www.linkedin.com/company/nuwaysag Adresse: Mittelweg 16-17, 20148 Hamburg, Germany ++++++++++ Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte. Offenlegung möglicher Interessenskonflikte nach § 85 WpHG beim oben analysierten Unternehmen befinden sich in der vollständigen Analyse. ++++++++++
The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
||||||||||||||||||||
2005619 10.10.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024e | ||
| Sales1 | 0,00 | 0,00 | 0,53 | 5,22 | 14,16 | 23,56 | 48,00 | |
| EBITDA1,2 | 0,00 | 0,00 | -0,56 | -0,83 | -2,51 | -0,25 | 3,60 | |
| EBITDA-Margin3 | 0,00 | 0,00 | -105,66 | -15,90 | -17,73 | -1,06 | 7,50 | |
| EBIT1,4 | 0,00 | 0,00 | -0,59 | -0,97 | -6,32 | -4,33 | -0,40 | |
| EBIT-Margin5 | 0,00 | 0,00 | -111,32 | -18,58 | -44,63 | -18,38 | -0,83 | |
| Net Profit (Loss)1 | 0,00 | 0,00 | -0,59 | -0,97 | -5,92 | 4,27 | -0,05 | |
| Net-Margin6 | 0,00 | 0,00 | -111,32 | -18,58 | -41,81 | 18,12 | -0,10 | |
| Cashflow1,7 | 0,00 | 0,00 | -0,56 | -0,83 | -2,11 | -0,20 | 0,00 | |
| Earnings per share8 | 0,00 | 0,00 | -0,05 | -0,08 | -0,47 | -0,34 | -0,01 | |
| Dividend per share8 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: PKF Wulf Gruppe
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| Cantourage Group | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A3DSV0 | DE000A3DSV01 | SE | 64,21 Mio € | 11.11.2022 | Kaufen | 9F4MF9M4+93 |
| PE 2025e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 57,22 | 36,78 | 1,56 | -51,50 | 1,60 | -77,83 | 2,73 |
|
Dividend '2022 in € |
Dividend '2023 in € |
Dividend '2024e in € |
Div.-Yield '2024e in % |
| 0,00 | 0,00 | 0,00 | 0,00% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 26.06.2024 | 15.05.2024 | 09.07.2024 | 07.11.2024 | 06.06.2024 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +7,92% | -15,30% | -28,27% | -27,67% | -20,52% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.
Contact
